De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Clinuvel Pharmaceuticals Inkomsten in het verleden
Verleden criteriumcontroles 4/6
Clinuvel Pharmaceuticals is de winst gegroeid met een gemiddeld jaarlijks percentage van 15.8%, terwijl de Biotechs industrie de winst jaarlijks groeide met 13.2%. De inkomsten zijn gegroeid met een gemiddelde snelheid van 22.9% per jaar. Het rendement op eigen vermogen van Clinuvel Pharmaceuticals is 17.6%, en het heeft een nettomarge van 40.4%.
Belangrijke informatie
15.8%
Groei van de winst
15.4%
Groei van de winst per aandeel
Biotechs Groei van de industrie | 9.6% |
Inkomstengroei | 22.9% |
Rendement op eigen vermogen | 17.6% |
Nettomarge | 40.4% |
Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
If EPS Growth Is Important To You, Clinuvel Pharmaceuticals (ASX:CUV) Presents An Opportunity
Aug 11Calculating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Jun 27Is Now The Time To Put Clinuvel Pharmaceuticals (ASX:CUV) On Your Watchlist?
May 09Estimating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Mar 24An Intrinsic Calculation For Clinuvel Pharmaceuticals Limited (ASX:CUV) Suggests It's 41% Undervalued
Nov 18Increases to Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Compensation Might Cool off for now
Oct 20Is Clinuvel Pharmaceuticals Limited (ASX:CUV) Trading At A 21% Discount?
Jul 30Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Could Be 27% Below Their Intrinsic Value Estimate
Feb 27Does Clinuvel Pharmaceuticals (ASX:CUV) Deserve A Spot On Your Watchlist?
Dec 14This Is The Reason Why We Think Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Might Be Underpaid
Nov 03A Look At The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Sep 23Here's Why I Think Clinuvel Pharmaceuticals (ASX:CUV) Might Deserve Your Attention Today
Jul 23With EPS Growth And More, Clinuvel Pharmaceuticals (ASX:CUV) Is Interesting
Apr 10Have Insiders Sold Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Recently?
Mar 06Earnings Miss: Clinuvel Pharmaceuticals Limited Missed EPS By 41% And Analysts Are Revising Their Forecasts
Feb 27What Is The Ownership Structure Like For Clinuvel Pharmaceuticals Limited (ASX:CUV)?
Feb 20Clinuvel Pharmaceuticals (ASX:CUV) Shareholders Have Enjoyed A Whopping 648% Share Price Gain
Feb 01Estimating The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Jan 14We Wouldn't Rely On Clinuvel Pharmaceuticals's (ASX:CUV) Statutory Earnings As A Guide
Dec 28Clinuvel Pharmaceuticals Limited's (ASX:CUV) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Dec 10What You Need To Know About Clinuvel Pharmaceuticals Limited's (ASX:CUV) Investor Composition
Nov 21Opbrengsten en kosten
Hoe Clinuvel Pharmaceuticals geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
30 Jun 24 | 88 | 36 | 29 | 2 |
31 Mar 24 | 85 | 33 | 29 | 2 |
31 Dec 23 | 82 | 30 | 29 | 1 |
30 Sep 23 | 80 | 30 | 27 | 1 |
30 Jun 23 | 78 | 31 | 25 | 1 |
31 Mar 23 | 74 | 29 | 23 | 1 |
31 Dec 22 | 70 | 26 | 21 | 1 |
30 Sep 22 | 68 | 24 | 20 | 1 |
30 Jun 22 | 66 | 21 | 19 | 1 |
31 Mar 22 | 62 | 22 | 18 | 1 |
31 Dec 21 | 57 | 24 | 17 | 1 |
30 Sep 21 | 53 | 24 | 16 | 1 |
30 Jun 21 | 48 | 25 | 14 | 1 |
31 Mar 21 | 43 | 23 | 14 | -1 |
31 Dec 20 | 38 | 21 | 14 | -3 |
30 Sep 20 | 35 | 18 | 13 | -1 |
30 Jun 20 | 33 | 15 | 12 | 0 |
31 Mar 20 | 32 | 15 | 10 | 4 |
31 Dec 19 | 32 | 15 | 8 | 8 |
30 Sep 19 | 32 | 16 | 7 | 7 |
30 Jun 19 | 31 | 18 | 6 | 7 |
31 Mar 19 | 29 | 17 | 6 | 7 |
31 Dec 18 | 27 | 16 | 6 | 6 |
30 Sep 18 | 26 | 15 | 6 | 6 |
30 Jun 18 | 25 | 13 | 6 | 6 |
31 Mar 18 | 21 | 10 | 6 | 5 |
31 Dec 17 | 17 | 6 | 6 | 5 |
30 Sep 17 | 17 | 7 | 6 | 4 |
30 Jun 17 | 17 | 7 | 5 | 4 |
31 Mar 17 | 14 | 5 | 5 | 4 |
31 Dec 16 | 12 | 3 | 4 | 4 |
30 Sep 16 | 9 | 0 | 4 | 4 |
30 Jun 16 | 7 | -3 | 5 | 4 |
31 Mar 16 | 5 | -5 | 3 | 3 |
31 Dec 15 | 4 | -6 | 2 | 3 |
30 Sep 15 | 4 | -8 | 4 | 3 |
30 Jun 15 | 3 | -10 | 6 | 3 |
31 Mar 15 | 3 | -10 | 8 | 3 |
31 Dec 14 | 3 | -10 | 9 | 3 |
30 Sep 14 | 3 | -8 | 7 | 3 |
30 Jun 14 | 3 | -6 | 5 | 3 |
31 Mar 14 | 3 | -6 | 5 | 3 |
31 Dec 13 | 2 | -6 | 5 | 3 |
Kwaliteitswinsten: CUV heeft een hoog niveau van non-cash earnings.
Groeiende winstmarge: De huidige netto winstmarges (40.4%) CUV } zijn hoger dan vorig jaar (39.1%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: De winst van CUV is de afgelopen 5 jaar met 15.8% per jaar gegroeid.
Versnelling van de groei: De winstgroei van CUV over het afgelopen jaar ( 16.4% ) overtreft het 5-jarig gemiddelde ( 15.8% per jaar).
Winst versus industrie: De winstgroei CUV over het afgelopen jaar ( 16.4% ) overtrof de Biotechs -sector 3.5%.
Rendement op eigen vermogen
Hoge ROE: Het Rendement op eigen vermogen ( 17.6% ) van CUV wordt als laag beschouwd.